leadf
logo-loader
viewPremier Farnell

Bid battle breaks out for Premier Farnell

Electronic parts distributor is recommending a 185p per share offer from US rival Avnet

Circuit board
Premier is withdrawing support for an earlier offer from Swiss engineer Daetwyler

Electronic parts distributor Premier Farnell plc (LON:PFL) has received a rival £691mln takeover bid.

Premier Farnell said it had decided to recommend a 185p per share offer from US component distributor Avnet Inc (NYSE:AVT), based in Phoenix, Arizona.

Premier said it was withdrawing support for an earlier offer from Swiss electro-mechanical engineering group Daetwyler AG (SWX:DAE), which valued it at £615mln.

Daetwyler had planned to merge Premier Farnell with its Daetwyler Technical Components UK division, resulting in a global technical parts business with about 4,900 staff and expected revenues of about £1.3bn.

Avnet said it believed a merger with Premier Farnell represented "a strong strategic fit and is highly attractive".

"Both companies share very similar strategic values and are highly complementary in terms of product range, distribution channels and geographic footprint," it said.

Premier Farnell directors, advised by investment bank Lazard and legal consultants Gibson Dunn, said they considered the financial terms of the transaction to be "fair and reasonable".

Quick facts: Premier Farnell

Price: - -

LSE:PFL
Market: LSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Bionomics' positive pharmacokinetic results confirms it can begin second...

Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De...

1 day, 9 hours ago

2 min read